Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2002
03/14/2002WO2001061001A3 Novel, central nervous protein, that modulates k+ flows
03/14/2002WO2001060396A3 Method for treating thyroid disorders
03/14/2002WO2001059129A3 Mammalian secreted group iii phospholipase a2
03/14/2002WO2001059064A3 Nucleic acids, proteins, and antibodies
03/14/2002WO2001058921A9 Methods and compositions for generating angiostatin
03/14/2002WO2001058918A3 Oligonucleotides modulating the expression of enzymes involved in the synthesis of melanic pigments
03/14/2002WO2001058852A3 (r)-2-aryl-propionamides, useful in the inhibition of il-8-induced chemiotaxis of neutrophils
03/14/2002WO2001057085A3 G-protein coupled receptors
03/14/2002WO2001057081A3 Narc-1, subtilase-like homologs
03/14/2002WO2001055410A3 Ceramidase compositions and methods based thereon
03/14/2002WO2001055392A3 Nuclear hormone receptors
03/14/2002WO2001055358A3 Phosphodiesterases
03/14/2002WO2001055312A3 Nucleic acids, proteins, and antibodies
03/14/2002WO2001055198A3 Dermo- and gastro-specific sphingolipid activator
03/14/2002WO2001055179A3 Nucleic acids encoding polypeptides with homology to olfactory receptors
03/14/2002WO2001054659A3 Slimming cosmetic composition comprising a plant extract containing a plant natriuretic peptide (pnp)
03/14/2002WO2001051512A3 Human and parasite orphan receptor proteins
03/14/2002WO2001051072A3 Antiparasitic agent
03/14/2002WO2001049728A3 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
03/14/2002WO2001049325A3 Gene therapy to promote angiogenesis and/or the treatment of heart failure
03/14/2002WO2001049264A3 Pharmaceutical compositions for oral administration
03/14/2002WO2001048162A3 Method for the production of vitamin a
03/14/2002WO2001046412A3 Interaction proteins for the stat transcription factor
03/14/2002WO2001044497A3 Protein kinase regulation
03/14/2002WO2001042290A3 Novel steroid-activated nuclear receptors and uses therefor
03/14/2002WO2001040472A3 Streptococcus pneumoniae antigens
03/14/2002WO2001036684A3 Mammalian toxicological response markers
03/14/2002WO2001035993A3 Compositions and methods for stimulating an immune response against infectious agents
03/14/2002WO2001032130A3 Phenyl amine carboxylic acid compounds and compositions for delivering active agents
03/14/2002WO2001027267A3 Genes differentially expressed in tr1 cells and their use in the manufacture of immunoregulatory compositions
03/14/2002WO2001023572A3 Polynucleotides and polypeptides encoded thereby
03/14/2002WO2001021651A3 Novel human protease inhibitor-like proteins and polynucleotides encoding the same
03/14/2002WO2001021194A3 Method for the therapeutic management of endometriosis and fallopian tube obstruction
03/14/2002WO2001020031A3 Polymorphisms in a klotho gene
03/14/2002WO2000066608A9 Tumor necrosis factor-gamma
03/14/2002WO2000065028A9 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
03/14/2002WO2000060083A9 Novel protein associated with cell stress response
03/14/2002WO2000058483A9 Protozoan expression system
03/14/2002WO2000056899A9 Dsp-2 dual-specificity map kinase phosphatase
03/14/2002WO2000053742A9 Polynucleotides and proteins encoded thereby
03/14/2002WO2000052047A9 Human dickkopf-related protein and nucleic acid molecules and uses therefor
03/14/2002WO1997003998A9 Modulators of the function of fas receptors and other proteins
03/14/2002US20020032488 Device for regeneration of articular cartilage and other tissue
03/14/2002US20020032463 Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue
03/14/2002US20020032346 Production of mixed acid anhydride and amide compound
03/14/2002US20020032323 Polynucleotide and polypeptide sequence information stored on computer readable media
03/14/2002US20020032322 Nucleic acid molecule coding for a protein having a potassium permeable membrane, comprising more than one P domains and three, four, five or more than six transmembrane segments.
03/14/2002US20020032314 Synthetic peptide neutrophil cell chemotactic agents
03/14/2002US20020032313 Vascular endothelial cell growth factor antagonists
03/14/2002US20020032312 Recombinant multispecific molecule comprising an anti-Fc receptor portion and an anti-target portion.
03/14/2002US20020032311 Interleukin-19
03/14/2002US20020032307 Hepadnavirus pre-S protein fragments
03/14/2002US20020032306 Cyclopeptide derivatives
03/14/2002US20020032234 First fatty acid compound that is a linoleic or linolenic compound and a second fatty acid that is a docosahexaenoic acid compound, an omega-3 or an omega-2 fatty acid or derivative
03/14/2002US20020032214 Pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound
03/14/2002US20020032175 Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
03/14/2002US20020032167 Increasing dwell time of fluid in a targeted area, administration of vascular permeablizing agent, and administration of a viral vector containing a gene expression cassette of interest
03/14/2002US20020032166 Biocompatible cationic detergents and uses therefor
03/14/2002US20020032165 Microspheres and adjuvants for DNA vaccine delivery
03/14/2002US20020032157 Methods of inhibiting ectopic calcification
03/14/2002US20020032156 Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders
03/14/2002US20020032155 Method of treating disc herniation and disc degeneration with concentrated growth and differentiation factors
03/14/2002US20020032154 Interferon-suppressing placental lactogen peptides
03/14/2002US20020032153 Methods and compositions for the treatment and prevention of erectile dysfunction
03/14/2002US20020032152 Anti-helicobacter vaccine complex
03/14/2002US20020032150 Regulaton of cytokine synthesis and release
03/14/2002US20020031831 Plasmid for use in vaccination and gene therapy
03/14/2002US20020031823 Use of trans-activation and CIS-activation to modulate the persistence of expression of a transgene
03/14/2002US20020031818 Modification of Mdm2 activity
03/14/2002US20020031817 Human matrix metalloprotease gene, proteins encoded therefrom and methods of using same
03/14/2002US20020031806 Purified human erythropoietin receptor protein fragment and antibodies derived therefrom
03/14/2002US20020031805 Polypeptide; for use in diagnosis and treatment of connective tissue defects
03/14/2002US20020031802 Novel seven transmembrane proteins and polynucleotides encoding the same
03/14/2002US20020031800 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/14/2002US20020031799 Mammalian coagulation protein; for use in treatment of blood disorders
03/14/2002US20020031798 Antibody recognizing human 25-hydroxyvitamin D3-1a-hydroxylase
03/14/2002US20020031793 Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
03/14/2002US20020031785 Splice variants of brca1 and brca2
03/14/2002US20020031560 Stabilized St. John's wort; antidepressant
03/14/2002US20020031557 Ascorbic acid composition and method for treatment of aging or damaged skin
03/14/2002US20020031545 Sustained-release preparation
03/14/2002US20020031539 Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
03/14/2002US20020031531 Immunotherapy for lung or urogenital cancer
03/14/2002US20020031529 Neurotoxin therapy for diabetes
03/14/2002US20020031522 Modified CD40 receptor-associated factor 1(CRAFI) gene prevents cell activation
03/14/2002US20020031520 Prevention and treatment of hepatocellular cancer
03/14/2002US20020031518 Lys-lys binding site I which is a plasminogen fragment consisting of Kringle 1 to Kringle 3 of a naturally occurring plasminogen with the N-terminal being lysine, which binding site binds to heparin
03/14/2002US20020031517 Administering an inhibitor of GDF-8, or a related member of Transforming Growth Factor-beta superfamily of structurally-related growth factors
03/14/2002US20020031515 Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
03/14/2002US20020031513 Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
03/14/2002US20020031512 Inhibiting immunological activation of keratinocytes by administering molecule that binds to CD40 but does not activate CD40-expressing keratinocytes
03/14/2002US20020031510 Contacting B7-positive cell with first soluble ligand which recognizes and binds B7 antigen, and contacting gp39-positive cell with second soluble ligand which recognizes and binds gp39 antigen; inhibiting rejection of transplanted tissues
03/14/2002US20020031508 Administering inducer of P-selectin activity such that hemostasis occurs
03/14/2002US20020031507 Treatment of inflammatory processes of the intestine, hypercholesterolaemia and infections with Helicobacter pylori; anticarcinogenic agent
03/14/2002US20020031506 Human glutathione peroxidase-6
03/14/2002US20020031505 Antitumor compositions containing taxane derivatives
03/14/2002US20020031504 Polyene macrolide antibiotic and at least one fungal cell wall degrading enzyme; for use in disinfectants or cosmetics
03/14/2002US20020031500 Delivery of therapeutic biologicals from implantable tissue matrices
03/14/2002US20020031499 Defective recombinant adenoviruses expressing cytokines for antitumor treatment
03/14/2002US20020031497 Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases